SUSTAINED RELEASE OPHTHALMOLOGICAL DEVICE AND METHOD OF MAKING AND USING THE SAME

• US 20060246112A1
• Filed: 07/14/2006
• Published: 11/02/2006
• Est. Priority Date: 01/18/2002
• Status: Abandoned Application

• Current Assignee: Eric M. Dobrusin, Michael E. Snyder
• Original Assignee: Eric M. Dobrusin, Michael E. Snyder
• Inventors: Snyder, Michael E., Dobrusin, Eric M.
• Application Number:
  US11/457,628
• Publication Number:
  US 20060246112A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 2/147 Implants to be inserted in the stroma for refractive correction, e.g. ring-like implants
• CPC Class Codes: A61F 2/1694 Capsular bag spreaders therefor
• CPC Class Codes: A61F 2002/1683 having filiform haptics
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device

Abstract

An ophthalmological implant including a layer of pharmaceutical agent and an overlying layer of a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof.

Claims

1. ) An ophthalmological implant comprising:

a. a filament configured for insertion into an eye;

b. a first layer including a pharmaceutical agent;

c. a second layer overlying the first layer and including a material selected from a bioerodible material, a biodegradable material, a bioavailable material or a mixture thereof.

4. ) The implant of claim 1, wherein the first and second layer selectively coats a portion of the filament.

5. ) The implant of claim 4, wherein the selective coating of the filament is selected from continuously, intermittently, uniformly, non-unifomrly, or a combination thereof.

6. ) The implant of claim 1, wherein the filament has a substantially uniformed thickness along its length.

7. ) The implant of claim 1, wherein the filament includes an arc-shaped “

J-loop”

, arc-shaped “

C-loop”

, a complete circumferential support member, a partial circumferential support member, a plate (e.g., a plate haptic configuration), a radial support member, a pararadial support member, a tangential support member, a circumferential support member, or a combination thereof.

8. ) The implant of claim 1, wherein the surface of the filament comprises a structure configured to receive the first layer selected from a well, divot, pore, groove, other types of crevices, or a combination thereof.

9. ) The implant of claim 1 wherein the pharmaceutical agent is selected from an antimicrobials, an antithrombotic, an antiseptic an antifungal, a chelating, an anticoagulant, antibiotic, an anti-inflammatory, a steroid, an antiglaucomatous or a combination thereof.

10. ) The implant of claim 1, wherein over a major portion of its length, the outer surface of the tension ring, having the first and second layer, is selected from a smooth surface an irregular surface, a stepped surface, a tapered surface, a surface having no slope or a combination thereof.

2. ) An endocapsular tension ring comprising:

a. a filament configured for insertion into an eye as an endocapsular tension ring;

b. a first layer including a pharmaceutical agent;

c. a second layer of variable thickness overlying the first layer and including a material selected from a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof, the second layer being dimensioned for prolonged release of the pharmaceutical agent from the ring as the second layer degrades.

11. ) The endocapsular tension ring of claim 2, wherein the first and second layer selectively coats a portion of the filament.

12. ) The endocapsular tension ring of claim 11, wherein the selective coating of the filament is selected from continuously, intermittently, uniformly, non-unifomrly, or a combination thereof.

13. ) The endocapsular tension ring of claim 2, wherein the filament has a substantially uniformed thickness along its length.

14. ) The endocapsular tension ring of claim 2, wherein the filament has a non-uniform thickness.

15. ) The endocapsular tension ring of claim 2, wherein the surface of the filament comprises one or more features configured to receive the first layer selected from a well, divot, pore, groove, other types of crevasses, or a combination thereof.

16. ) The endocapsular tension ring of claim 2, wherein the pharmaceutical agent is selected from an antimicrobials, an antithrombotic, an antiseptic, an antifungal, a chelating, an anticoagulant, antibiotic, an anti-inflammatory, a steroid, an antiglaucomatous or a combination thereof.

17. ) The endocapsular tension ring of claim 2, wherein over a major portion of its length, the outer surface of the tension ring is selected from a smooth surface an irregular surface, a stepped surface, a tapered surface, a surface having no slope or a combination thereof.

3. ) A method for making an endocapsular tension ring comprising the steps of:

a. providing a filament configured for insertion into an eye as an endocapsular tension ring;

b. attaching a first layer including a pharmaceutical agent to the filament;

c. attaching a second layer of variable thickness over the first layer, the second layer including a material selected from a bioerodible material a biodegradable material a bioavailable material or a mixture thereof, and the second layer being dimensioned for prolonged release of the pharmaceutical agent from the filament as the second layer degrades.

18. ) The endocapsular tension ring of claim 3, wherein the pharmaceutical agent is selected from 5-fluorouracil (5-FU), cyclosporine A (CsA), vancomycin, ganciclovir, fluocinolone acetonide, dexamethasone, daunorubicin, indomethacin, timolol, mitomycin-C, or mixtures thereof.

19. ) The endocapsular tension ring of claim 3, wherein over a major portion of its length, the outer surface of the tension ring is selected from a smooth surface an irregular surface, a stepped surface, a tapered surface, a surface having no slope or a combination thereof.

20. ) The endocapsular tension ring of claim 19, wherein over a major portion of its length, the outer surface of the tension ring is selected from a smooth surface an irregular surface, a stepped surface, a tapered surface, a surface having no slope or a combination thereof.